ESMO 2022 | OpACIN and OpACIN-neo: Neoadjuvant immunotherapy for advanced melanoma

Judith Versluis, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the OpACIN (NCT02437279) and OpACIN-neo (NCT02977052) trials, which investigated neoadjuvant immunotherapy (IO) for patients with advanced melanoma. OpACIN involved 10 patients treated with neoadjuvant IO and 10 treated with adjuvant IO. The neoadjuvant treatment resulted in a high response rate but also had high toxicity. OpACIN-neo therefore investigated a variety of dosing schedules and involved 86 patients across 3 arms of the trial. Dr Versluis discusses the 5 year survival data from OpACIN and 3 year survival data from OpACIN-neo. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.